Patents Assigned to Boston Medical Center Corporation
  • Patent number: 11324799
    Abstract: The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 10, 2022
    Assignees: ZEALAND PHARMA A/S, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Bjarne Due Larsen, Ulrik Mouritzen, Dongjoon Kim, Sayon Roy
  • Publication number: 20210403521
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 30, 2021
    Applicant: Boston Medical Center Corporation
    Inventors: Steven C. BORKAN, Zhiyong WANG
  • Patent number: 11136363
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 5, 2021
    Assignee: Boston Medical Center Corporation
    Inventors: Steven C. Borkan, Zhiyong Wang
  • Patent number: 11124769
    Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a MEP precursor cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) modulator. In some embodiments the AhR modulator is an AhR antagonist. In some embodiments the AhR modulator is an AhR agonist. In some embodiments the methods comprise culturing MEP precursor cells in the presence of an AHR antagonist and then culturing MEP precursor cells in the presence of an AHR agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR modulator are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: September 21, 2021
    Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITY
    Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
  • Patent number: 11122784
    Abstract: This application provides a novel mouse model (PLA2g6 KOEx2) in which genetic deletion of the N terminus of PLA2g6 results in a loss of dopaminergic (DA) neurons in substantia nigra (SN), and development of PD-like motor deficits that can be significantly improved by L-DOPA. Based in part on experimental results demonstrated with this model, this disclosure provides genetically modified animals and genetically modified animal cells that comprise a mutant allele of PLA2g6 and in which store-operated Ca2+ entry (SOCE) is impaired and ER Ca2+ stores are depleted. This disclosure also provides methods of screening a compound for an effect on the SOCE pathway and/or ER Ca2+ by administering the compound to such a genetically modified animal or genetically modified animal cell.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: September 21, 2021
    Assignee: Boston Medical Center Corporation
    Inventor: Victoria Bolotina
  • Publication number: 20210207100
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 8, 2021
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE
  • Publication number: 20210121263
    Abstract: The inventions provided herein relate to tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 29, 2021
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Mark W. GRINSTAFF, Boris Nicolas BLOCH, Jonah KAPLAN
  • Patent number: 10906955
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 2, 2021
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
  • Patent number: 10842816
    Abstract: The technology described herein relates, at least in part, to compositions comprising and methods for isolating and enriching natural IgM-producing phagocytic B (NIMPAB) cells and methods of producing IgM antibodies using such cells, as well as uses of the antibodies produced by the methods for the prevention and treatment of diseases wherein immunotherapy with such natural IgM antibodies and their derivatives can be useful.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: November 24, 2020
    Assignees: Trustees of Boston University, Boston Medical Center Corporation
    Inventors: Xuemei Zhong, Joyce Wong
  • Patent number: 10732354
    Abstract: A system for analyzing a tissue sample includes two wavelength-division multiplexers and a fiber coupler. The first wavelength-division multiplexer combines visible and near infrared electromagnetic radiation and directs the combined electromagnetic radiation to the fiber coupler. The fiber coupler emits a sample beam of visible and near infrared electromagnetic radiation toward a tissue sample, and a reference beam of visible and near infrared electromagnetic radiation toward a reference mirror. The sample beam reflects off the tissue sample back to the fiber coupler. The reference beam reflects off the reference mirror back to the fiber coupler. The fiber coupler combines the reflected sample and reference beams and directs the combined electromagnetic radiation to the second wavelength-division multiplexer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 4, 2020
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Ji Yi, Weiye Song
  • Patent number: 10617794
    Abstract: Provided herein are methods comprising the use of a macroinitiator and application protocols to apply a hydrophilic coating to latex, or natural rubber, and compositions resulting from such methods. This coating results in e.g., an increased sense of lubrication when in contact with water or an aqueous solution.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 14, 2020
    Assignees: Trustees of Boston University, Boston Medical Center Corporation
    Inventors: Mark W. Grinstaff, Stacy L. Chin, Ruiqing Xiao, Benjamin Goldman Cooper, Karen Buch, Ducksoo Kim
  • Patent number: 10575753
    Abstract: Methods of making a white matter fibrogram representing the connectome of the brain of a subject, comprising: (a) performing a multispectral multislice magnetic resonance scan on the brain of a subject, (b) storing image data indicative of a plurality of magnetic resonance weightings of each of a plurality of slices of the brain of the subject to provide directly acquired images, (c) processing the directly acquired images to generate a plurality of quantitative maps of the brain indicative of a plurality of qMRI parameters of the subject, (d) constructing a plurality of magnetic resonance images indicative of white matter structure from the quantitative maps, and (e) rendering a white matter fibrogram of the brain of the subject from the plurality of magnetic resonance images.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: March 3, 2020
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Hernan Jara
  • Publication number: 20200054602
    Abstract: The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 20, 2020
    Applicants: ZEALAND PHARMA A/S, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Bjarne Due LARSEN, Ulrik MOURITZEN, Dongjoon KIM, Sayon ROY
  • Patent number: 10544393
    Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 28, 2020
    Assignee: Boston Medical Center Corporation
    Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
  • Patent number: 10525119
    Abstract: Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: January 7, 2020
    Assignee: Boston Medical Center Corporation
    Inventor: Richard N. Goldstein
  • Patent number: 10390521
    Abstract: This application provides a novel mouse model (PLA2g6 KOEx2) in which genetic deletion of the N terminus of PLA2g6 results in a loss of dopaminergic (DA) neurons in substantia nigra (SN), and development of PD-like motor deficits that can be significantly improved by L-DOPA. Based in part on experimental results demonstrated with this model, this disclosure provides genetically modified animals and genetically modified animal cells that comprise a mutant allele of PLA2g6 and in which store-operated Ca2+ entry (SOCE) is impaired and ER Ca2+ stores are depleted. This disclosure also provides methods of screening a compound for an effect on the SOCE pathway and/or ER Ca2+ by administering the compound to such a genetically modified animal or genetically modified animal cell.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: August 27, 2019
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Victoria Bolotina
  • Publication number: 20190256567
    Abstract: One aspect of the technology relates to methods, assays and kits to identify ischemia and ischemic injury, including kidney injury, and are useful in determining efficacy of cancer treatments. In particular, differential phosphorylation of the nucleophosmin (NPM) polypeptide is an early marker of ischemic injuries such as kidney injury, AKI and ischemic renal cell injury. Another aspect of the technology relates to compositions and methods for the treatment of ischemia and kidney injury, including NPM inhibitory agents, including, but not limited to NPM inhibitory peptides for the treatment of ischemia and kidney injury.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 22, 2019
    Applicant: Boston Medical Center Corporation
    Inventors: Steven C. BORKAN, Zhiyong WANG
  • Patent number: 10358677
    Abstract: Provided herein are methods for the treatment of chronic kidney disease and proteinuria and for the diagnosis of chronic kidney disease and monitoring the effects of treatment on the progression of chronic kidney disease and proteinuria based on unexpected roles for the SLIT-ROBO signaling pathway in the regulation of podocyte F-actin cytoskeleton and foot process structure in the kidney.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 23, 2019
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Weining Lu, Xueping Fan, David J. Salant
  • Patent number: 10337995
    Abstract: A method for constructing a three-dimensional image of a sample includes producing electromagnetic radiation and directing the produced electromagnetic radiation such that it is incident on the sample at an oblique angle. The incident electromagnetic radiation is scanned in discrete increments to a plurality of discrete locations along a first direction, and at each discrete location, scanned along a second direction orthogonal to the first direction. The sample reflects a first portion of the incident electromagnetic radiation and absorbs a second portion of the incident electromagnetic radiation, and emits electromagnetic radiation responsive to the absorption. A plurality of cross-sectional images is produced from the reflected electromagnetic radiation and the emitted electromagnetic radiation, and each cross-sectional image is modified to compensate for the oblique angle. The modified cross-sectional images are then combined to create a three-dimensional image of the sample.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 2, 2019
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Ji Yi
  • Patent number: 10314810
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: June 11, 2019
    Assignees: Trustees of Boston University, Northeastern University, Boston Medical Center Corporation
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere